Pharma Times
NOVEMBER 25, 2021
A team of scientists and pharmaceutical collaborators have discovered a ‘bench to bedside’ drug design, which will hopefully improve the future treatment of Alzheimer’s disease.
pharmaphorum
NOVEMBER 16, 2021
An artificial intelligence algorithm developed by GE Healthcare that helps with the placement of endotracheal tubes (ETTs) has been approved by the FDA. The new tool – part of GE’s Critical Care Suite 2.0 – helps bedside staff and radiologists assess patients before intubation – for example prior to ventilation in patients with critical COVID-19 – and make sure their ETTs are positioned correctly.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NY Times
NOVEMBER 27, 2021
A new treatment using stem cells that produce insulin has surprised experts and given them hope for the 1.5 million Americans living with the disease.
Outsourcing Pharma
NOVEMBER 16, 2021
CRISPR Therapeutics and ViaCyte, Inc. have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D).
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Patent Watch
NOVEMBER 30, 2021
Annual Drug Patent Expirations for FLOVENT+HFA Flovent Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from four suppliers. There are…. The post New patent expiration for Glaxo Grp drug FLOVENT HFA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
NOVEMBER 2, 2021
Open enrollment is under way for the 2022 Medicare Part D plans. Our exclusive analysis of Center for Medicare & Medicaid Services’ (CMS) data reveals that preferred cost sharing pharmacy networks will maintain their dominance as an established component of Part D benefit design. For 2022: 98% of stand-alone Medicare Part D prescription drug plans (PDP) will have a preferred network. 66% of Medicare Advantage prescription drug (MA-PD) plans will have a preferred network.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
pharmaphorum
NOVEMBER 28, 2021
An investigator-led trial of Jazz Pharma’s cannabis extract-based drug Sativex in glioblastoma – an aggressive form of brain cancer – will get underway in the UK next year. The three-year phase 2 trial will be carried out by researchers at Leeds University led by professor of clinical oncology and neuro-oncology Susan Short, and see if adding Sativex (nabiximols) to standard chemotherapy for recurrent glioblastoma can extend survival.
NY Times
NOVEMBER 28, 2021
A “Frankenstein mix” of mutations raises concerns, but the variant may remain vulnerable to current vaccines. If not, revisions will be necessary.
Outsourcing Pharma
NOVEMBER 25, 2021
A new clinical trial of heterologous â or âmix-and-matchâ â combinations of COVID-19 vaccines is set to start in Pakistan: seeking to add to research on the effectiveness of such combinations.
Drug Patent Watch
NOVEMBER 10, 2021
Annual Drug Patent Expirations for ARISTADA+INITIO+KIT Aristada Initio Kit is a drug marketed by Alkermes Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Alkermes Inc drug ARISTADA INITIO KIT appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Channels
NOVEMBER 16, 2021
In Consolidation and Preferred Pharmacy Networks in 2022’s Medicare Part D Plans , I highlighted how those networks have hijacked the world of stand-alone Medicare Part D prescription drug plans (PDP) and become a major presence in Medicare Advantage prescription drug (MA-PD) plans. Today, I examine the largest retail chains’ participation in the 21 major 2022 Part D preferred networks that the eight largest plan sponsors will offer.
Pharma Times
NOVEMBER 11, 2021
ChAdOxl biEBOV is being tested for safety and immunogenicity, and may protect against multiple species of the virus
pharmaphorum
NOVEMBER 12, 2021
Researchers in the US have developed an artificial intelligence-based tool that is able to predict COVID-19 symptoms and suggest which FDA-approved drugs might be used to treat patients. The MOATAI-VIR algorithm, developed by scientists at Emory University and Georgia Tech, was put through its paces in a study that showed it was able to predict 24 out of 26 clinical manifestations of COVID-19, including acute respiratory distress, blood clotting issues, cytokine storms, brain fog, and loss of sm
NY Times
NOVEMBER 16, 2021
The company announced a deal that could help significantly expand access to the Covid-19 treatment, but the agreement excludes a number of countries hit hard by the pandemic.
Outsourcing Pharma
NOVEMBER 29, 2021
The biotech firm has presented data from a study that could offer hope to patients with Parkinsonâs, Gaucher, Alzheimerâs and other neurodegenerative conditions.
Drug Patent Watch
NOVEMBER 14, 2021
Annual Drug Patent Expirations for AMTURNIDE Amturnide is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug. This drug has one…. The post New patent expiration for Novartis drug AMTURNIDE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
NOVEMBER 19, 2021
Today’s guest post comes from Carolyn Zele, Senior Manager of Solution Enablement at MMIT. Carolyn describes how oncology pathways were developed to help standardize treatment and ensure quality care. She argues, however, that these pathways often shut manufacturers out of the market. Click here to learn more about MMIT's Pulse Analytics solution , which provides insight into payer- and pathway-driven barriers to access.
Pharma Times
NOVEMBER 24, 2021
With the latest approval from the EC, patients in Europe suffering from metastatic triple-negative breast cancer can now receive Gilead Science’s Trodlevy as part of their treatment.
pharmaphorum
NOVEMBER 3, 2021
A real-world study of digital therapeutic (DTx) for opioid use disorder has found that patient show used it had 46% fewer hospital stays than a control group, saving more than $2,700 over a nine-month period. The study of Pear Therapeutics’ reSET-O found that the total cost of hospital and clinician costs were $11,141 among 64 patients who were prescribed the DTx but didn’t use it, but fell to $8,733 among active users of the 12-week course.
NY Times
NOVEMBER 16, 2021
The antiviral drugs have helped inspire hope among senior administration officials that the United States will be able to curb the devastating toll from the Delta variant.
Outsourcing Pharma
NOVEMBER 29, 2021
A leader from the health tech solutions company explains how progress in genetic testing has helped advance the detection and prevention of breast cancer.
Drug Patent Watch
NOVEMBER 26, 2021
Annual Drug Patent Expirations for VIBERZI Viberzi is a drug marketed by Allergan Holdings and is included in one NDA. It is available from one supplier. There are sixteen patents…. The post New patent for Allergan Holdings drug VIBERZI appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Marketing Network
NOVEMBER 8, 2021
November 3, 2021 – Tune in with the Pharma Marketing Network for an exciting conversation with R.J. Lewis and David Hunt, CEO of The Considered, as he shares how his new independent agency, The Considered, about how they are breaking the rules in pharma advertising. David discusses and answers questions around: How The Considered is different. What launched the conception of the agency?
Pharma Times
NOVEMBER 29, 2021
Analyses provided by UK cancer charity Macmillan has provided insights into the repercussions experienced by patients waiting to receive treatment during the COVID-19 pandemic.
pharmaphorum
NOVEMBER 16, 2021
Amazon’s push into the provision of remote healthcare services has been rewarded with a top-tier corporate client – the Hilton hotel chain. The deal – first reported by Reuters – involves the Amazon Care platform, which includes remote, online consultations with clinicians, as well as home visits in some areas. It provides primary and preventive care, ongoing support for chronic conditions, and referrals to secondary and tertiary care.
NY Times
NOVEMBER 19, 2021
If the C.D.C. agrees, adults who received a second shot of the Pfizer or Moderna vaccine at least six months ago could be eligible by this weekend.
Outsourcing Pharma
NOVEMBER 22, 2021
The US agency has granted approval to Voxzogo, an injectable drug designed to aid growth in children with achondroplasia, the most common form of dwarfism.
Drug Channels
NOVEMBER 30, 2021
ICYMI, CVS Health recently announced that it will close about 900 of its retail pharmacies. This downsizing complements the company’s shift toward its healthcare delivery future. This long-overdue move highlights the retail industry’s fundamental economic headwinds. The pharmacy shakeout is accelerating, as smaller competitors exit and larger companies reduce store count.
Drug Patent Watch
NOVEMBER 4, 2021
Annual Drug Patent Expirations for MYCAPSSA Mycapssa is a drug marketed by Chiasma and is included in one NDA. It is available from one supplier. There are seven patents protecting…. The post New patent for Chiasma drug MYCAPSSA appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
NOVEMBER 5, 2021
The trial evaluated the investigational medicine in non-hospitalised adult patients with COVID-19 who are at high-risk of progressing to severe illness
pharmaphorum
NOVEMBER 16, 2021
Moderna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of its technology has been shown in a new AstraZeneca-partnered candidate for heart failure. At the American Heart Association (AHA) congress, the two partners presented results from the phase 2a EPICCURE trial that showed that injecting their AZD8601 candidate directly into the heart muscle of patients undergoing coronary artery bypass graft (CABG) surgery seemed to improve heart functio
NY Times
NOVEMBER 23, 2021
This is the first jury verdict in an opioid case. The decision embraced a key legal argument that judges in other opioid cases had recently rejected.
Outsourcing Pharma
NOVEMBER 10, 2021
Stevanato Group is showcasing its SG Alina disposable, variable-dose pen injector platform, available with customizable features, at CPhI Worldwide 2021.
Drug Channels
NOVEMBER 9, 2021
The Food & Drug Administration (FDA) recently approved the first interchangeable biosimilar insulin product: the insulin glargine-yfgn injection from Viatris. Read the FDA’s press release. Alas, I’m sad to report that the warped incentives baked into the U.S. drug channel will limit the impact of this impressive breakthrough. Viatris is being forced to launch both a high-priced and a low-priced version of the biosimilar.
Drug Patent Watch
NOVEMBER 4, 2021
Annual Drug Patent Expirations for SAVELLA Savella is a drug marketed by Allergan and is included in one NDA. It is available from three suppliers. There are four patents protecting…. The post New patent expiration for Allergan drug SAVELLA appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
156 
Let's personalize your content